More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin ... NovoLog and Novo Nordisk’s other rapid-acting insulin follow-on Fiasp are among the drugs ...

Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).

With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...

Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

has a shorter duration of action than other long-acting basal insulins like Sanofi's Lantus (insulin glargine) and biosimilars and Novo Nordisk's newer product Tresiba (insulin degludec), but is ...

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Up until a few years ago, Novo Nordisk was mainly known for selling insulin and other diabetes ... high single-digit annual percentage over the long run. Novo Nordisk has raised earnings per ...

The drug, which is the first rapid-acting biosimilar ... Merilog (insulin-aspart-szjj, Sanofi-Aventis U.S.) was approved as biosimilar to Novolog (Novo Nordisk) for improving blood sugar control ...